Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: A pilot study

Critical Care

Volumn 10, Issue 3, 2006, Pages

  Rommers, Mirjam K ^a,b   Van Der Lely, Netty ^c   Egberts, Toine C G ^a,d   van den Bemt, Patricia M L A ^a,d  

^a GGZ Midden Brabant   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CPRLab   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE; CREATININE; DALTEPARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG MECHANISM; EDEMA; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SCORING SYSTEM; SEX RATIO; SUBCUTANEOUS TISSUE; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; DRUG EFFECTS; FOLLOW UP; INTENSIVE CARE UNIT; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SKIN ABSORPTION; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DALTEPARIN; EDEMA; FACTOR XA; FACTOR XA INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SUBCUTANEOUS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PILOT PROJECTS; SKIN ABSORPTION; TIME FACTORS;

EID: 34447645667     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc4952     Document Type: Article

References (31)

1. Attia J Ray JG Cook DJ Douketis J Ginsberg JS Geerts WH Deep vein thrombosis and its prevention in critically ill adults Arch Intern Med 2001 161 1268-1279 10.1001/archinte.161.10.1268 11371254
2. Geerts W Selby R Prevention of venous thromboembolism in the ICU Chest 2003 124 357S-363S 10.1378/chest.124.6_suppl.357S 14668418
3. Alikham R Cohen AT Combe S Samama MM Desjardins L Eldor A Janbon C Leizorovicz A Olsson C-G Turpie ACG Risk factors for venous thromboembolism in hospitalised patients with acute medical illness: analysis of the MEDENOX study Arch Inter Med 2004 164 963-968 10.1001/ archinte.164.9.963
4. Cook D McMullin J Hodder R Heule M Pinilla J Dodek P Stewart T Prevention and diagnosis of venous thromboembolism in critically ill patients: A Canadian sturvey Crit Care 2001 5 336-342 83855 11737922 10.1186/cc1066
5. Lacherade JC Cook D Heyland D Chrush C Brochard L Brun-Buisson C Prevention of venous thromboembolism in critically ill medical patients: a Franco-Canadian cross-sectional study J Crit Care 2003 18 228-237 14691896 10.1016/j.jcrc.2003.10.006
6. Nurmohamed MT Rosendaal FR Buller HR Dekker E Hommes DW Vandenbroucke JP Briet E Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis Lancet 1992 340 152-156 10.1016/ 0140-6736(92)93223-A 1352573
7. Leizorovicz A Haugh MC Chapuis FR Samama MM Boissel JP Low molecular weight heparin in prevention of perioperative thrombosis BMJ 1992 305 913-920 1281030
8. Mismetti P Laporte-Simitsidis S Tardy B Cucherat M Buchmüller Juillard-Delsart D Decousus H Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials Thromb Haemost 2000 83 14-19 10669147
9. Samama MM Cohen AT Darmon J-Y Desjardins L Eldor A Janbon C Leizorovicz A Nguyen H Olsson C-G Turpie AG Weisslinger N A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients N Engl J Med 1999 341 793-800 10477777 10.1056/ NEJM199909093411103
10. Leizorovicz A Cohen AT Turpie ACG Olsson C-G Vaitkus PT Goldhaber SZ Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients Circulation 2004 110 874-879 10.1161/01.CIR.0000138928.83266.24 15289368
11. Dörffler-Melly J de Jonge E de Pont AC Meijers J Vroom MB Buller HR Levi M Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors Lancet 2002 359 849-850 10.1016/ S0140-6736(02)07920-5 11897286
12. Priglinger U Delle Karth G Geppert A Joukhadar C Graf S Berger R Hülsmann M Spitzauer S Pabinger I Heinz G Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003 31 1405-1409 10.1097/ 01.CCM.0000059725.60509.A0 12771610
13. Freedman MD A bioavailability study in the proposed patient population - with much more needed now Crit Care Med 2003 31 1588-1589 10.1097/ 01.CCM.0000059726.55857.C5 12771643
14. Krishnan V Murray P Pharmacologic issues in the critically ill Clin Chest Med 2003 24 671-688 10.1016/S0272-5231(03)00096-0 14710697
15. Ariza-Andraca CR Altamirano-Bustamante E Frati-Munari AC Altamirano-Bustamante P Graef-Sanchez A Delayed insulin absorption due to subcutaneous edema Arch Invest Med (Mex) 1991 22 229-233 1819999
16. Cadroy Y Pourrat J Baladra MF Saivin S Houin G Montastruc JL Vernier I Boneu B Delayed elimination of enoxaparine in patients with chronic renal insufficiency Thromb Res 1991 63 385-390 10.1016/ 0049-3848(91)90141-I 1659748
17. Collignon F Frydman A Caplain H Ozoux ML Le Roux Y Bouthier J Thébault JJ Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (dose for prevention of thromboembolism) Thromb Haemost 1995 73 630-640 7495071
18. Frydman A Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans Haemostasis 1996 26 Suppl 2 24-38 8707165
19. Duplaga BA Rivers CW Nutescu E Dosing and monitoring of low-molecular-weight heparins in special populations Pharmacotherapy 2001 21 218-234 10.1592/phco.21.2.218.34112 11213859
20. Wilson SJA Wilbur K Burton E Anderson DR Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism Haemostasis 2001 31 42-48 10.1159/000048043 11408748
21. Boneu B de Moerloose P How and when to monitor a patient treated with low molecular weight heparin Semin Thromb Hemost 2001 27 519-522 10.1055/ s-2001-17961 11668422
22. Sanderink GJCM Guimart CG Ozoux ML Jariwala NU Shukla UA Boutouyrie BX Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment Thromb Res 2002 105 225-231 10.1016/S0049-3848(02)00031-2 11927128
23. Levine MN Planes A Hirsh J Goodyear M Vochelle N Gent M The relationship between anti factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement Thromb Haemost 1989 62 940-944 2556813
24. Bara L Planes A Samama MM Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery Br J Haematol 1999 104 230-240 10.1046/j.1365-2141.1999.01153.x 10050702
25. Desjardins L Bara L Boutitie F Samama MM Cohen AT Combe S Janbon C Leizorovicz A Olsson C-G Turpie AGG Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the medenox study Arch Pathol Lab Med 2004 128 519-526 15086284
26. Mayr AJ Dünser M Jochberger S Fries D Klingler A Joannidis M Hasibeder W Schobersberger W Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin Thromb Res 2002 105 201-204 10.1016/S0049-3848(02)00028-2 11927124
27. Rutherford EJ Schooler WG Sredzienski E Abrams JE Skeete DA Optimal dose of enoxaparin in critically ill trauma and surgical patients J Trauma 2005 58 1167-1170 15995464
28. Vincent JL de Mendonça A Cantraine F Moreno R Takala J Suter PM Sprung CL Colardyn F Blecher S Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicentric, prospective study Crit Care Med 1998 26 1793-1800 9824069
29. Ferreira FL Bota DP Bross A Mélot C Vincent JL Serial evaluation of the SOFA score to predict outcome in critically illpatients JAMA 2001 286 1754-1758 10.1001/jama.286.14.1754 11594901
30. Nagge J Crowther M Hirsch J Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002 162 2605-2609 10.1001/archinte.162.22.2605 12456233
31. Bazinet A Almanric K Brunet C Turcotte I Martineau J Caron S Blais N Lalonde L Dosage of enoxaparin among obese and renal impairment patients Thromb Res 2005 116 41-50 10.1016/j.thromres.2004.10.004 15850607